Geneva, Nov. 2 -- International Clinical Trials Registry received information related to the study (NCT07893093) titled 'A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Two Formulations of ASC36 Injection in Participants With Obesity or Overweight' on Oct. 19.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).
Primary Sponsor: Ascletis Pharma (China) Co., Limited
Condition:
Chronic Weight Management
Intervention:
Drug: ASC36 Injection A, for subcutaneous use
Drug: ASC36 Placebo Injection A, for subcutaneous use
Drug: ASC36 Injection B, for subcutane...